Noticias Marker Therapeutics Inc - MRKR | Acciones NASDAQ

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Form 8-K - Current report

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated...

Form 8-K - Current report

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage...

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was...

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained...

ShadowHaven59 1 hora hace

I’ve noticed a change in the frequency of responses from the company lately. in the last two years, I have never received a response, but in the last two months, I have received a response from my last two emails to the company, not sure it means anything, but I thought I would just post it in the chat room anyway. thank you everyone for your valuable information.

👍️0

learningcurve2020 11 horas hace

Have you ever asked them why they don't address their shareholders on quarterly calls /Q&A but instead seem to rely on you to communicate?

👍️0

Phantom Lord 23 horas hace

It's grant money.

👍️0

microcapbiotech 24 horas hace

Interesting cancer article. "Groundbreaking clinical trial cures cancer in 100% of patients."
https://www.msn.com/en-us/health/other/groundbreaking-clinical-trial-cures-cancer-in-100-of-patients/ar-AA1uqFJg?ocid=msedgdhp&pc=U531&cvid=be9d60cda7174620ee78a7879d0f9022&ei=45
Which brings up a question that I asked about 2 years ago, WHY doesn't MRKR use their Multi TAA, (now called MAR) ALONG WITH a checkpoint inhibitor that blocks the PD-1 protein on T-cells? Never got an answer to that.

👍️ 1

Flyingj 1 día hace

Anybody know where the 1.92 million in sales came from this quarter? Is part of it right to try patients

👍️0

Phantom Lord 1 día hace

Very tight lipped on the data. Just that they are encouraged by what they are seeing but I would expect them to say that regardless of what is happening with the trial.

👍️ 1

ShadowHaven59 1 día hace

Thank you

👍️0

learningcurve2020 1 día hace

I never imagined a one trick pony biotech could put out a fresh 10q and forget to update their shareholders on the trial. Seems impossible.

👍️0

CorsairNavigator20 1 día hace

Were you able to ask about data subsets. My line of conjecture would be they saw a commonality in patients with good outcomes, approached the FDA to narrow the indication and had to increase sample size. Only positive reason why it's taking forever. Yes that will really change the future of this company. Just trying to keep a positive spin. Were you able to get them to talk data at all or tell you it is going to be the greatest thing since sliced bread.

👍️0

learningcurve2020 1 día hace

If the treatment is showing good efficacy it should be a cinch to enroll such small numbers. So it begs the question, why would they sabotage their own company?

👍️0

learningcurve2020 1 día hace

Not a good sign for Marker, IMO. Should've been Marker not Kalaris. Nobody wants to talk about here, of course.

https://www.biopharmadive.com/news/allovir-kalaris-reverse-merger-retina-diseases/732385/

👍 1

Phantom Lord 1 día hace

This is only partly true. They stopped the MT401 AML PII trial to refocus their efforts in AML on the OTS version of MT401. That trial was supposed to start by the end of this year but true to form the company blew right by their own timeframe. It's supposed to start first half of next year now, IIRC. Who really knows if this will end up being the right decision or not.

👍️ 2

Phantom Lord 1 día hace

I'm not worried about bad data. I'm worried that management is making poor decisions in their execution of the release. Ah86 hit the nail on the head. Their problem has always been trickling out data on an inconsequential number of patients. It's great to see the CRs but when the total number of patients you're reporting on is 3, no one is going to care. They need a bigger number. I believe they know this but in my communications with the company they are very reluctant to share the enrollment numbers. That worries me. Originally the trial was supposed to enroll 37 patients. No reason it should not be fully enrolled by now at 37 patients. That being said, back in May the enrollment on clinicaltrials.gov was increased to 79. Take with that what you will. Basically, the company needs data on more patients. They gave us the data on the initial 3 as a "tease" or indicator of how the trial started but the next data release better be at least 30 patients. There is no excuse for anything less than that.

👍️ 2

ah86 1 día hace

oh i'm not missing a thing except that i'm dumbfounded that a bunch of folks would be pessimistic having sunk a ton of money in an investment.
Talk about paradox, oh my!
An alien, if given the same facts, would bet that these folks are confident of success.

👍️0

learningcurve2020 1 día hace

The market cap is now that of a promising in vitro experiment.

👍️0

Buckboard 1 día hace

Thanks. The thing you are missing is many of us on here would NOT walk away "with a few bucks" selling now. We're already down a ton and would lock in big losses. My theory is hope for the best because biggest losses already in even if they close shop. I am a pessimist like B Franklin so have no big hopes here.

👍️0

learningcurve2020 1 día hace

Shrugs.

👍️0

learningcurve2020 1 día hace

Already in penny stock land with a horrible $25M market cap. It's the small amount of shares outstanding thanks to the reverse split that's throwing you off.

👍️0

microcapbiotech 2 días hace

That definition is obvious and simple for even the most simple to comprehend. Bad data is the kind of data that gets trials CANCELED like the AML trials were.

👍️0

ah86 2 días hace

Yes, you're wrong on some fronts. This is an open label trial. You can see failure from across the Atlantic. No company as is the case with this one, can have 'bad data' and put it in the fridge.
Patience is key here. Just over 3 bucks. You may walk away with some $$ if you sell now, though I don't know your avg cost per share. But for those that are impatient, they should pray N is greater than 10 otherwise you're back to pennystock land. The stuff works but on just 3 people is apparently equivalent to 'bad data'
If they post at minimum similar results on a greater number and you may call yourself a genius for picking this ticker.

👍️ 1

ah86 2 días hace

Define bad data,and you'll answer yourself.

👍️0

learningcurve2020 2 días hace

2029

👍️0

Buckboard 2 días hace

I may be wrong about this and PL will definitely know but it was my understanding that if they had the data collected and it was bad, they had to release that info within a few days. Otherwise, people would be still buying stock while the company withheld bad news.

👍️ 1

microcapbiotech 2 días hace

This company never produced bad data?? Is that why the AML trials were canceled?? because they produced good AML data??
I guess good data is why the website went from having several trials going to just one trial now.

👍️0

ah86 2 días hace

Allow me. The data isn't bad. This company has never produced bad data. Period.
The problem has always been? wait for it, drum roll - N
You can't get heads to turn with N being 2 or 3.
And that exactly, without doubt, is what is taking this so long. And failing to provide enough of N will cause this to slip like it hit a banana peel.

👍️ 1

ShadowHaven59 2 días hace

Phantom Lord, what is the latest date you would give this company to show the data before you would start thinking that the data is bad? thank you.

👍️0

learningcurve2020 4 días hace

So, this Marker board member pays Marker cash to buyout their manufacturing start up facility, then he becomes a contractor where Marker pays him millions quarterly for what exactly we're not sure. The company oddly cancels all their agreements to raise cash. All as MRKR provides no update on the progress of their one trial. Do I have that right so far?

https://markertherapeutics.com/our-company/board-of-directors/

👍 1

Phantom Lord 5 días hace

Love that ignore button, lol

👍️ 5 🫣 1

ah86 5 días hace

I found the ignore button. Such a blessing!

👍️0

learningcurve2020 5 días hace

I wouldn't worry about under or over at this point, I'd worry about stealing your IP, assuming you're a shareholder, of course.

👍️0

ShadowHaven59 5 días hace

For what it’s worth, I emailed the company, Stating if upper management believes in the platform. They should buy some shares on the open market as a sign of confidence for the market and shareholders. I doubt anything will happen, but hey you never know. I can’t tell if the shares are under priced or overvalued. Lol.

👍️0

learningcurve2020 5 días hace

You mean when he allegedly talks to managment? Don't you think a normal shareholder would want to comment on that last 10Q having no update on the trial?

🚫 2 ❌️ 2

travayl 5 días hace

Phantom generally posts when he has information to share.

👋 1 👍️ 1

learningcurve2020 5 días hace

Phantom goes silent, of course.

🙈 1 🙉 1

learningcurve2020 1 semana hace

Because I do believe in this T cell tech, I'm actually more worried they're trying to slip it out the back door as we wait for something that may never come. Feels that way.

👍️0

learningcurve2020 1 semana hace

I saw that. But I'm not sure 34% is bad in biotech?? LOL. It's more about what you bet heavy on. Seems like maybe 5% of biotech investors actually do well. It's a racket, IMO.

👍️0

PonkenPlonken 1 semana hace

I think its driftwood for a while
Too bad they didnt follow up on funding or anything at all

👍️0

CorsairNavigator20 1 semana hace

Check out his track record, it's 34%. And yes they do investment banking.

👍️0

CorsairNavigator20 1 semana hace

I hear the pain, I go back to the days after the Tapimmune merger. You should be used to the inability of this group to meet commitments. I am waiting for the data and would like to know why a phase 1 needs 31 patients which has not been fully enrolled. I have 100% expectations they will do the dilution at that point. Zombies move faster. I try to use humor to keep from getting upset. Doesn't always work

👍️0

learningcurve2020 1 semana hace

Geez, you're angry. Just quickly scanned the 10q for a trial update but recall this:

In August 2021, we entered into a Controlled Equity OfferingSM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which we can offer and sell, from time to time at our sole discretion through the Sales Agents, shares of our common stock having an aggregate offering price of up to $75.0 million. Any shares of our common stock sold will be issued pursuant to our shelf registration statement on Form S-3 (File No. 333-258687), which the SEC

👍️0

jobynimble 1 semana hace

Did they end the Cantor ATM too?

You can’t be serious, just more proof that you do zero due diligence and just get a kick out of trying to be a disruptor…

👍️0

learningcurve2020 1 semana hace

Pretty hostile response for a nothing. Did they end the Cantor ATM too?

👍️0

ah86 1 semana hace

Somebody should take away all your devices. What fcking open ATM with Cantor are you talking about?
Yes, you are wrong.

👍️0

learningcurve2020 1 semana hace

I hope analyst Dr. Huseynov's call wastn't just another retail trap.

👍️0

learningcurve2020 1 semana hace

This is no start up. They're burning through what little cash they have and I think with only one open ATM source with Cantor?? The CEO seems disinterested in holding calls. Right now it's feeling like another Take the money and run scenario. Look at Tap and AlloVir. History is important and it's up to this CEO to tell us things are different with this one. Really hope I'm wrong on this one but that 10q and the lack of a call was an absolute disgrace.

👍️0

PonkenPlonken 1 semana hace

too bad no follow up on the funding... or anything else.

👍️0

Flyingj 1 semana hace

I think MRKRs management team should have to get in the ring with Tyson tomorrow night. Especially if his an investor.

👍️ 1

CorsairNavigator20 1 semana hace

When I worked startup, we used to joke some of them were a room full of PhDs looking for a product.
I am truly hoping that they are looking at some CRs and see if they fit a subgroup to focus on for phase2. I have no idea but we will wait and find out. That could be a great Christmas present. Actually I have very little faith that they will let us know in the fourth quarter. It could be Easter.

👍️ 2

learningcurve2020 1 semana hace

Don't think I've ever been in a biotech that failed to mention in the 10q the progress of their one trial. Can only mean no progress since the last 10q?? Seems impossible. Meanwhile Cell Ready / Director of Marker is being paid handsomely for services but for what exactly? No quarterly call either. Terrible. What's going on here?

👍️0

ShadowHaven59 1 semana hace

I am also frustrated and disappointed coming home to this news! I also received today a response from the company from my email, it states, I understand your frustrations and appreciate your patience. we are currently working towards providing a comprehensive Data update and are looking forward to sharing this with our investors after completions of some remaining details. we appreciate your patience as we finalize These steps. this is for the smarter people than myself, to try and analyze. thank you I appreciate all your opinions and information. Very very frustrated shareholder.

👍️ 1

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Marker Therapeutics Inc (MRKR)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

MRKR Noticias

Form 8-K - Current report

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

MRKR Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Marker Therapeutics Inc (MRKR) Noticias

Marker Therapeutics Inc (MRKR)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

MRKR Noticias

Form 8-K - Current report

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Form 8-K - Current report

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

Form 8-K - Current report

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

MRKR Discussion

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación